New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
06:33 EDTFMI, CLVSFoundation Medicine and Clovis Oncology partner for cancer diagnostic
Foundation Medicine (FMI) and Clovis Oncology (CLVS) are expanding their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a novel Premarket Approval companion diagnostic test. This test is designed for use by physicians to identify patients most likely to respond to rucaparib, Clovis’ poly polymerase inhibitor currently the subject of Phase 2 and Phase 3 clinical trials in patients with ovarian cancer. This companion diagnostic is being developed in parallel with the clinical development of rucaparib to facilitate an FDA submission of the PMA for the companion diagnostic concurrent with the New Drug Application for rucaparib.
News For FMI;CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
12:52 EDTFMIFoundation Medicine management to meet with JMP Securities
Subscribe for More Information
07:15 EDTCLVSASCO / ASTRO / IASLC to hold symposium
Subscribe for More Information
October 23, 2014
16:54 EDTCLVSClovis announces first patient enrolled in lucitanib Phase 2 study
Clovis Oncology announced that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer, or NSCLC, has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the company’s oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta. The Phase 2 study will enroll FGFR1-amplified squamous NSCLC patients with advanced disease who have progressed on at least one prior line of therapy. The global study will assess objective response rate, progression-free survival, and duration of response, as well as the safety, tolerability, and pharmacokinetics of lucitanib.
October 22, 2014
08:22 EDTFMIFoundation Medicine, WuXi PharmaTech announce strategic collaboration
Foundation Medicine (FMI) and WuXi PharmaTech (WX) announced a collaboration to offer Foundation Medicine’s comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China. Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine’s FoundationOne assay at the WuXi Genome Center in Shanghai, the first and only CLIA-certified laboratory in China. Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.
08:13 EDTFMIFoundation Medicine, WuXi PharmaTech announce collaboration
Subscribe for More Information
October 17, 2014
06:31 EDTFMIFoundation Medicine upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use